U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H26N2S
Molecular Weight 314.488
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERGOLIDE

SMILES

CCCN1C[C@H](CSC)C[C@H]2[C@H]1CC3=CNC4=C3C2=CC=C4

InChI

InChIKey=YEHCICAEULNIGD-MZMPZRCHSA-N
InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H26N2S
Molecular Weight 314.488
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.scripintelligence.jp/wp-content/uploads/2014/05/12-January-2005-Heart-valve-disease-warning-for-pergolide-in-Europe.pdf | https://www.medicines.org.uk/emc/PIL.2413.latest.pdf?isAttachment=true&documentid=2413 | https://www.ncbi.nlm.nih.gov/pubmed/23769407

Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. Pergolide stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors and are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors and has been associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2- and D3-receptors. It also exhibits agonist activity on dopamine D4, D1, and D5, 5-hydroxytryptamine (5-HT)1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, α2A-, α2B-, α2C-, α1A-, α1B-, and α1D-adrenergic receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion. Pergolide also causes transient increases in somatotropin (growth hormone) secretion and decreases in luteinizing hormone (LH) concentrations. Pergolide is not available for use by humans in the United States, but approved for veterinary use; it was used in various other countries for the treatment of various conditions including Parkinson's disease, hyperprolactinemia, and restless leg syndrome. Pergolide in Europe was indicated for Parkinson's disease only when other dopaminergic agonist treatments had failed, and treatment had to be initiated by a neurologist. The label warned against using doses of more than 5mg a day, whether alone or in combination with levodopa. However the marketing of this drug finally stopped in France in May 2011 and sales elsewhere in Europe ceased eventually.

Originator

Curator's Comment: # Eli Lilly

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
127 ng/mL
0.25 mg 3 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
209 ng/mL
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
472 ng/mL
1 mg 3 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
573 ng × h/mL
0.25 mg 3 times / day steady-state, oral
dose: 0.25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1094 ng × h/mL
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2392 ng × h/mL
1 mg 3 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.8 h
0.5 mg 3 times / day steady-state, oral
dose: 0.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
138 μg single, oral
dose: 138 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
PERGOLIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Disc. AE: Rash, Syncope...
AEs leading to
discontinuation/dose reduction:
Rash (grade 2-3)
Syncope (grade 3)
Sources:
1 mg 3 times / day steady, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: steady
Dose: 1 mg, 3 times / day
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Disc. AE: Diarrhea, Dyskinesia...
AEs leading to
discontinuation/dose reduction:
Diarrhea (1%)
Dyskinesia (1%)
Dystonia (1%)
Headache (1%)
Liver disorder (1%)
Nausea and vomiting (2.9%)
Parkinsonism aggravated (1%)
Sleep disorder (1%)
Urinary incontinence (1%)
Sources:
14 mg multiple, oral
Overdose
unhealthy
Other AEs: Movements involuntary, Tingling...
Other AEs:
Movements involuntary (grade 3)
Tingling (grade 3)
Sources:
19 mg multiple, oral
Overdose
unhealthy
Other AEs: Hallucinations...
60 mg single, oral
Overdose
healthy
Other AEs: Vomiting, Hypotension...
7 mg single, oral
Overdose
unhealthy
Other AEs: Palpitations, Hypotension...
7 mg single, oral
Overdose
unhealthy
Other AEs: Ventricular extrasystoles...
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Daytime sleepiness, Hypotension symptomatic...
Other AEs:
Daytime sleepiness
Hypotension symptomatic (10%)
Sources:
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Daytime sleepiness...
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Drug-induced hallucinosis...
Other AEs: Drug-induced hallucinosis...
AEs leading to
discontinuation/dose reduction:
Drug-induced hallucinosis (grade 3, 3%)
Other AEs:
Drug-induced hallucinosis (14%)
Sources:
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Pleuritis, Pleural effusion...
Other AEs:
Pleuritis (rare)
Pleural effusion (rare)
Pleural fibrosis (rare)
Pericarditis (rare)
Pericardial effusion (rare)
Cardiac valvulopathy (rare)
Retroperitoneal fibrosis (rare)
Sources:
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Other AEs: Hallucinations, Confusion...
AEs

AEs

AESignificanceDosePopulation
Rash grade 2-3
Disc. AE
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Syncope grade 3
Disc. AE
0.05 mg single, oral
Recommended
Dose: 0.05 mg
Route: oral
Route: single
Dose: 0.05 mg
Sources:
unhealthy, 46 - 75
Health Status: unhealthy
Age Group: 46 - 75
Sex: M+F
Sources:
Diarrhea 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Dyskinesia 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Dystonia 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Headache 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Liver disorder 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Parkinsonism aggravated 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Sleep disorder 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Urinary incontinence 1%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Nausea and vomiting 2.9%
Disc. AE
2.2 mg multiple, oral
Recommended
Dose: 2.2 mg
Route: oral
Route: multiple
Dose: 2.2 mg
Sources:
unhealthy, 65.5 ± 9.5
Health Status: unhealthy
Age Group: 65.5 ± 9.5
Sex: M+F
Sources:
Movements involuntary grade 3
14 mg multiple, oral
Overdose
unhealthy
Tingling grade 3
14 mg multiple, oral
Overdose
unhealthy
Hallucinations grade 3
19 mg multiple, oral
Overdose
unhealthy
Agitation
60 mg single, oral
Overdose
healthy
Hypotension
60 mg single, oral
Overdose
healthy
Vomiting
60 mg single, oral
Overdose
healthy
Hypotension
7 mg single, oral
Overdose
unhealthy
Palpitations
7 mg single, oral
Overdose
unhealthy
Ventricular extrasystoles
7 mg single, oral
Overdose
unhealthy
Daytime sleepiness
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Hypotension symptomatic 10%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Daytime sleepiness common
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Drug-induced hallucinosis 14%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Drug-induced hallucinosis grade 3, 3%
Disc. AE
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Cardiac valvulopathy rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pericardial effusion rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pericarditis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleural effusion rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleural fibrosis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Pleuritis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Retroperitoneal fibrosis rare
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Confusion 1.8%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Hallucinations 7.8%
1 mg 3 times / day multiple, oral
Recommended
Dose: 1 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1 mg, 3 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
1999 Dec
Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.
1999 Mar
Sleep attacks and Parkinson's disease treatment.
2000 Apr 15
Sleep attacks (sleep episodes) with pergolide.
2000 Apr 15
Adverse outcomes in a controlled trial of pergolide for cocaine dependence.
2001
Switching from pergolide to pramipexole in patients with Parkinson's disease.
2001
[Parkinson's disease].
2001 Mar 3
[A 64-year-old man with parkinsonism as an initial symptom followed by dementia associated with marked abnormal behaviours].
2001 Nov
Pergolide mesilate may improve fatigue in patients with Parkinson's disease.
2001-2002
Restless legs syndrome in the older adult: diagnosis and management.
2002
[Treatment of Parkinson's syndrome].
2002
A new design of a polysomnography-based multi-center treatment study for the restless legs syndrome.
2002 Apr
Valvular heart disease in patients taking pergolide.
2002 Dec
Drug-related valvular heart disease: here we go again: will we do better this time?
2002 Dec
Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
2002 Dec
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
2002 Jan
Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2).
2002 Jan 2
[Pergolide: a useful agonist for the treatment of Parkinson disease].
2002 Jul
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.
2002 May
Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.
2002 Nov
Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Dopamine agonist monotherapy in Parkinson's disease.
2002 Nov 30
Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
2002 Nov-Dec
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease.
2002 Oct
The effect of pergolide on cognitive performance of young and middle-aged rats.
2002 Sep
Pergolide-induced pleuropulmonary fibrosis.
2002 Sep-Oct
Dopamine agonists induce episodes of irresistible daytime sleepiness.
2003
The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
2003 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Administration of Pergolide mesylate tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. Pergolide mesylate tablets are usually administered in divided doses 3 times per day. During dosage titration, the dosage of concurrent l-dopa/carbidopa may be cautiously decreased.
Route of Administration: Oral
Pergolide (10 umol/L) depolarized PASMC membrane potential from 51.11.5 to 44.00.8 mV in resistance PASMCs. In CHO cells, pergolide (10(-7) to 10(-5) mol/L) inhibited heterologously expressed rat BKCa channels in a dose-dependent manner.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:31 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:31 GMT 2025
Record UNII
24MJ822NZ9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERGOLIDE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PERGOLIDE [MI]
Preferred Name English
Pergolide [WHO-DD]
Common Name English
pergolide [INN]
Common Name English
PERGOLIDE [VANDF]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 108197
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
LIVERTOX NBK548593
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
WHO-ATC N04BC02
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
NDF-RT N0000000117
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
NDF-RT N0000175767
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
CFR 21 CFR 520.1705
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
NCI_THESAURUS C66884
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
WHO-VATC QN04BC02
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
NDF-RT N0000007620
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
NCI_THESAURUS C38149
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
Code System Code Type Description
RXCUI
8047
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY RxNorm
DAILYMED
24MJ822NZ9
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
PUBCHEM
47811
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
MERCK INDEX
m8547
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL531
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
MESH
D010479
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
DRUG BANK
DB01186
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
WIKIPEDIA
PERGOLIDE
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
NCI_THESAURUS
C61886
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID2023438
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
IUPHAR
48
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
INN
4651
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
CAS
66104-22-1
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
SMS_ID
100000082732
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
DRUG CENTRAL
2105
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
CHEBI
63617
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
FDA UNII
24MJ822NZ9
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
EVMPD
SUB09725MIG
Created by admin on Mon Mar 31 18:07:31 GMT 2025 , Edited by admin on Mon Mar 31 18:07:31 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
BINDER->LIGAND
BINDING
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC